The invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.
HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS
申请人:Pfizer Products Inc.
公开号:EP1841757B1
公开(公告)日:2010-06-30
US7429665B2
申请人:——
公开号:US7429665B2
公开(公告)日:2008-09-30
US7825254B2
申请人:——
公开号:US7825254B2
公开(公告)日:2010-11-02
[EN] HETEROAROMATIC QUINOLINE COMPOUNDS<br/>[FR] COMPOSES DE QUINOLINE HETEROAROMATIQUES
申请人:PFIZER PROD INC
公开号:WO2006072828A2
公开(公告)日:2006-07-13
[EN] The invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders. [FR] L'invention concerne des composés hétéroaromatiques qui sont utilisés comme inhibiteurs efficaces de la phosphodiesterase (PDE). D'une manière plus spécifique, l'invention concerne des composés hétéroaromatiques qui sont des inhibiteurs sélectifs de la PDE10. L'invention concerne également des intermédiaires pour la préparation de ces composés ; des compositions pharmaceutiques contenant ces composés ; et l'utilisation de ces composés dans une méthode permettant de traiter certains troubles du système nerveux central ou autres.